Regulators fast-track gene editing for neonatal...
CMN Clinical
Jan. 21, 2026
A genome-wide CRISPR-Cas9 screen identifies Rab5A as potential hepatitis E drug target
By: Gorm Palmgren - Dec. 19, 2023
CMN Intelligence - The World’s Most Comprehensive Intelligence Platform for CRISPR-Genomic Medicine and Gene-Editing Clinical Development
Providing market intelligence, data infrastructure, analytics, and reporting services for the global gene-editing sector. Read more...
Targeted silencing of Rab5A and related endosomal proteins notably reduced HEV RNA replication, while late endosome components had no effect. Pharmacological inhibition of Rab5A also decreased replication in a dose-dependent manner.
Co-localisation studies suggest Rab5A and early endosomes as scaffolds for HEV replication complexes, shedding light on HEV lifecycle and host interactions essential for infection.
The study was published yesterday in PNAS: https://doi.org/10.1073/pnas.2307423120
To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.
Tags
Latest News
CLINICAL TRIALS
IND Enabling
Phase I
Phase II
Phase III
Gastric Cancer and Colorectal Cancer, CRC, (NCT07166263)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
